Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback